| Document Date: 2013-07-21 04:57:48
Open Document File Size: 167,27 KBShare Result on Facebook
City London / / / / IndustryTerm active site / biotechnology-derived medicinal products / biological/biotechnology-derived therapeutic proteins / individual products / biological medicinal products / biological products / given product / biotechnological medicinal product / physical and chemical nature / biotechnology-derived proteins / biotechnology / biotechnology-derived pharmaceuticals / reference product / biological medicinal product / age / analogous product / biological product / sample processing/storage / biosimilar products / risk management / biological/biotechnology-derived proteins / biotechnology-derived therapeutic proteins / non-recombinant expression systems / infusion devices / medicinal products / infusion solutions / manufacturing processes / similar biological medicinal products / e.g. breakdown products / manufacturing process / / MedicalCondition absence/dysfunction / bronchospasm / disease / headache / chills / nausea / anaphylaxis / fever / metastatic disease / chronic infections / urticaria / each disease / patient’s underlying disease / hypersensitivity / anaphylactic reactions / e.g. malnutrition / dizziness / pruritus / back pain / HIV disease / wheezing / hypotension / / Organization European Medicines Agency London / COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE / / / Position EXECUTIVE / CONTENTS EXECUTIVE / / Technology pharmacokinetics / antibodies / BIOTECHNOLOGY / / URL http /
SocialTag |
Microsoft Word - GL-Immunogenicity assessment of therapeutic proteins